Session 3 Flashcards
(122 cards)
What are the possible Aetiology of abnormal phenotypes in Balanced Karyotypes ?
Disruption of a gene by breakpoints
Cryptic imbalance
Position effect
Disturbance of imprinting
UPD
Involvement of X chromsome
What are the two mechanisms of disease in Osteogenesis Imperfecta (OI)?
How do they differ in phenotype?
Haploinsufficiency (OI type 1 )
- Less severe disease with NMD of null variants causing reduction in amount of protein
Dominant negative (OI type II, III and IV)
- more severe disease. Disrupt formation of collagen helix (mainly glycine losses) so effect both alleles
What is SMA?
What is the frequency?
Spinal Muscular atrophy (AR)
Estimated incidence of 1 in 6,000 to 1 in 10,000
Carrier frequency of 1/40 to 1/60 ( ~ 1/50 in the UK)
Most frequent genetic cause of infant mortality
What is the overall phenotype of SMA?
Wweakness and paralysis of voluntary muscles due to degeneration of Anterior horn motor neurons in the spinal cord.
* Progressive proximal, symmetrical limb and trunk muscle weakness (typically lower limbs before upper)
*Intercostal muscle weakness that results in breathing difficulties.
* Fine tremor in the fingers
* Muscle twitches in tongue (fasciculation) result in poor suck and swallow with increasing swallowing and feeding difficulty over time
* Facial weakness
How does prenatal SMA present?
Prenatal SNA - arthrogryposis multiplex congenita, absence of movement except for extraocular and facial movement, death usually occurs from respiratory failure before age one month
How does Type 1 SMA present?
- Most common form, accounts for 60% of all SMA patients
- Typically diagnosed before six months
- Present with profound hypotonia and symmetrical flaccid paralysis (“floppy baby”)
- Progressive weakness at infancy – death at an early age.
- Lack of motor development: Inability to lift head, poor head control, never able to sit without support.
- Swallowing and feeding can be difficult due to tongue fasciculation
- Mild contractures at the knee joint and absence of tendon reflexes
- Aspiration pneumonia is an important cause of morbidity and mortality (usually before the age of 2)
How does Type 2 SMA present?
- Intermediate subtype – accounts for 27% SMA patients.
- Age of onset of muscle weakness is between 6 - 12 months
- Low muscle tone
- These children may be able to sit unaided, but will never be able to walk without support
- Finger trembling common
- Absent tendon reflexes in 70% of cases
- Life expectancy is significantly reduced but ~70% of patients reach adulthood
How does Type 3 SMA present?
- ~12% of SMA patients.
- Includes clinically heterogeneous patients
- Can usually stand and walk alone, but may show difficulty walking at some point
- Proximal muscular weakness develops in infancy: legs more severely affected than arms
- Onset usually after age ten months; patients can be subdivided into 2 groups depending on age of onset:
o IIIa is diagnosed before 3 years
o IIIb after 3 years
How does Type 4 SMA present?
Type IV SMA (Adult onset)
* The onset of muscle weakness is usually in the second or third decade of life.
* Normal life expectancy.
* ~1% SMA patients
* The findings are similar to those described for SMA III
Outline the SMN region
Two genes in SMN region on 5q12.2q13.3- SMN1 and SMN2
SMN1 is telomeric and SMN2 is centromeric
Most people have 1 SMN1 on each chromosome, but 4% people have 2 copies on 1 chromosome. SMN2 copy number ranges from 0-5 (in tandem cis configuration).
SMN1 and SMN2 differ by 5 base pairs - critical one being c.840c>T in exon 7. This change effects exon 7 splicing and means that exon is missing in 90% of SMN2 transcripts which are then non-functional.
What is the function of the SMN protein?
ubiquitously expressed, and abundant in motor neurons of the spinal cord
SMN forms a complex with Gemin proteins and acts as a chaperone to assist in the assembly of U small nuclear ribonuclear protein (snRNPs). SMN is an essential component of the spliceosome and is localized to novel nuclear structures called ‘gems’. Loss SMN predicted to cause either in impaired mRNA production and the neurons become deficient in proteins or SMN required for mRNA transport along axon.
SMN is essential and loss of SMN1 (and no SMN2) is not compatible with life
What is most SMN1 common genotype for patient with SMA?
~95-98% are homozygous for a deletion of at least exon 7 of SMN1 (whole gene deletions or smaller) Can also be gene conversions to SMN2
What are the more rare SMN1 genotypes for patient with SMA?
~2-5% are compound heterozygous for a deletion of at least exon 7 of SMN1 and a pathogenic inactivating mutation in SMN1 detectable by sequence analysis
<1% are homozygous for a pathogenic inactivating mutation in SMN1
What percentage of SMN1 deletions are de novo?
~2% (usually paternal in origin)
What is SMN2 copy number an indicator for?
Severity - increased SMN2 copies relate to less severe disease
What drug was previously used most for SMA?
Nusinersen - modulated SMN2 splicing to produce more functional mRNA. But required multiple injections and not a cure
What treatment is now available for SMA type 1 from NICE?
Zolgensma - gene therapy - deliver SMN1 in viral vector before 13 months
What imprinted region is responsible for for BWS and RSS?
11p15 imprinting cluster
What is normal imprinting pattern and expression of 11p15?
Two imprinting centres at work:
IC1 - regulates IGF2 - a fetal growth factor, and H19 - non-translated mRNA that may function as a tumor suppressor. On paternal allele IC1 is methylated - H19 not expressed and IGF2 is expressed. On maternal allele IC1 is not methylated - H19 expressed and works on enhancer of IGF2 to stop its expression.
IC2 - regulates KCNQ1, KCNQ1OT1(non-coding RNA with antisense transcription to KCNQ1) and CDKN1C (cyclin dependent kinase inhibitor which arrests the cell cycle in G1). On paternal allele no methylation and KCNQ1OT1 inhibits KCNQ1 and CDKN1C expression. On maternal allele - methylation imcludes KCNQ1OT1 promoter and stops its expression. KCNQ1 and CDKN1C are expressed.
What are the clinical features of BWS?
Paediatric overgrowth disorder with estimated incidence of 1 in 13,700
Positive family history of BWS, Macrosomia, Macroglossia, Omphalocele, Visceromegaly, Embryonal tumor, Cleft palate (rare)
What percentage of BWS are sporadic?
And what are the types?
~85%
IC2 hypomethylation 50-60% (mosaic): due to loss (complete or partial) of maternal methylation at IC2
Paternal UPD (~20%) mainly mosaic - IC1 hypermethylation and hypomethylation of IC2
CDKN1C point mutation (5-10%) - associated with cleft palate
IC1 hypermethylation 2-7% (mosaic): IC1 gain of methylation on maternal allele
Translocations/Inversions (<1%).
What is first line testing for BWS in most cases?
MS-MLPA
What other types of testing are used for BWS and why?
CDKN1C sequencing - family history and cleft palate
Karyotype - for structural abnormalities
Name two other overgrowth syndromes
Costello - HRAS
Sotos - NSD1